Myasthenia Gravis clinical trials at UC Cancer

• Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  open to eligible people ages 18 years and up

  This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

  at UC Irvine

• Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  open to eligible people ages 18-74

  The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

  at UC Irvine

Last updated: July 13, 2021